Cargando…

Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score

Background: There is not yet an effective marker in predicting the efficacy of immune checkpoint inhibitors (ICIs) in treating hepatocellular carcinoma (HCC) patients. The Gustave Roussy Immune Score (GRIm-Score) based on three objective variables, namely, neutrophil-to-lymphocyte ratio (NLR), serum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yongjiang, Pan, Yangxun, Lin, Ximeng, Hou, Jingyu, Hu, Zili, Xu, Li, Zhou, Zhongguo, Zhang, Yaojun, Chen, Minshan, Hu, Dandan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883391/ https://www.ncbi.nlm.nih.gov/pubmed/35237150 http://dx.doi.org/10.3389/fphar.2021.819985

Ejemplares similares

Gustave Roussy Immune Score (GRIm-Score) is a prognostic marker in patients with resectable esophageal squamous cell carcinoma
por: Feng, Ji-Feng, et al.
Publicado: (2020)

The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Prognostic value of modified-Gustave-Roussy Immunity Score in resectable proximal gastric cancer
por: Shi, Yujing, et al.
Publicado: (2023)

Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2019)

Prognostic significance of the Gustave Roussy immune (GRIm) score in cancer patients: a meta-analysis
por: Sun, Ke-Xin, et al.
Publicado: (2023)

Survival benefit of preoperative hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin followed by hepatectomy for hepatocellular carcinoma
por: Hu, Zili, et al.
Publicado: (2023)

A Systemic Inflammation Response Score for Prognostic Prediction in Hepatocellular Carcinoma Patients After Hepatectomy
por: Zhang, Deyao, et al.
Publicado: (2022)

Laparoscopic Hepatectomy versus Open Hepatectomy After Conversion Therapy Using Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy for Patients with Initially Unresectable Hepatocellular Carcinoma
por: Yang, Zhenyun, et al.
Publicado: (2023)

Gustave Roussy Immune Score as a Novel Prognostic Scoring System for Colorectal Cancer Patients: A Propensity Score Matching Analysis
por: Tian, Shan, et al.
Publicado: (2021)

Systemic Inflammation Score Using Pretherapeutic Inflammatory Markers to Predict Prognosis for Hepatocellular Carcinoma Patients After Hepatic Arterial Infusion Chemotherapy
por: Wu, Tianqing, et al.
Publicado: (2023)

Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2020)

Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation
por: Hu, Zili, et al.
Publicado: (2022)

Tumor Location Influences Oncologic Outcomes of Hepatocellular Carcinoma Patients Undergoing Radiofrequency Ablation
por: Chen, Jinbin, et al.
Publicado: (2018)

Development and validation of robust metabolism‐related gene signature in the prognostic prediction of hepatocellular carcinoma
por: Pan, Yangxun, et al.
Publicado: (2023)

Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor
por: Minami, Seigo, et al.
Publicado: (2019)

Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma
por: Yang, Zhenyun, et al.
Publicado: (2022)

Tenofovir versus Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma After FOLFOX-Hepatic Arterial Infusion Chemotherapy
por: Zheng, Zhikai, et al.
Publicado: (2023)

Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study
por: Shangguan, Jian, et al.
Publicado: (2023)

A Nomogram Based on Preoperative Lab Tests, BMI, ICG-R15, and EHBF for the Prediction of Post-Hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma
por: Zhang, Deyao, et al.
Publicado: (2022)

Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus
por: Hu, Zili, et al.
Publicado: (2023)

A novel inflammation‐based nomogram system to predict survival of patients with hepatocellular carcinoma
por: Chen, Jinbin, et al.
Publicado: (2018)

Effect of prior cancer on survival of hepatocellular carcinoma: implications for clinical trial eligibility criteria
por: Sun, Xuqi, et al.
Publicado: (2021)

Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy
por: Theodore, Ch, et al.
Publicado: (2004)

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
por: Recondo, Gonzalo, et al.
Publicado: (2020)

Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors
por: Zhang, Rujia, et al.
Publicado: (2023)

Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis
por: Chen, Jinbin, et al.
Publicado: (2018)

Hepatic Arterial Infusion Chemotherapy as a Timing Strategy for Conversion Surgery to Treat Hepatocellular Carcinoma: A Single-Center Real-World Study
por: Wang, Jiongliang, et al.
Publicado: (2022)

A monocyte/granulocyte to lymphocyte ratio predicts survival in patients with hepatocellular carcinoma
por: Zhou, Dongsheng, et al.
Publicado: (2015)

The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab
por: Lenci, Edoardo, et al.
Publicado: (2021)

Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study
por: Fu, Yizhen, et al.
Publicado: (2020)

Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy
por: Sun, Xuqi, et al.
Publicado: (2020)

Liver Tumor Markers, HALP Score, and NLR: Simple, Cost-Effective, Easily Accessible Indexes for Predicting Prognosis in ICC Patients after Surgery
por: Zhang, Deyao, et al.
Publicado: (2022)

A cohesin‐associated gene score may predict immune checkpoint blockade in hepatocellular carcinoma
por: Liu, Cui‐Zhen, et al.
Publicado: (2022)

1688P Outcome of older cancer patients infected with COVID-19 at Gustave Roussy Cancer Center
por: Hauchecorne, M., et al.
Publicado: (2020)

High expression of TACC2 in hepatocellular carcinoma is associated with poor prognosis
por: Shakya, Manjul, et al.
Publicado: (2018)

Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization
por: ZHOU, DONGSHENG, et al.
Publicado: (2016)

The mutation of hepatitis B virus and the prognosis of hepatocellular carcinoma after surgery: a pilot study
por: Zhang, Yaojun, et al.
Publicado: (2018)

Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
por: Long, Teng, et al.
Publicado: (2023)

Impact of missing individual patient data on 18 meta-analyses of randomised trials in oncology: Gustave Roussy experience
por: Fayard, Florence, et al.
Publicado: (2018)

Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic
por: Patrikidou, Anna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ht3lsr69t3mq3ce4h25d4qu5mt